Actively Recruiting
Study of ASP5834 to Find Suitable Doses and Evaluate Safety in Adults With Advanced Solid Tumors Having KRAS Mutations or Amplifications
Led by Astellas Pharma Inc · Updated on 2026-10-29
404
Participants Needed
22
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying ASP5834 in adults with certain locally advanced, unresectable, or metastatic solid tumors that have specific KRAS gene mutations or amplifications. This study aims to understand how ASP5834 works in the body, find a suitable dose, and evaluate safety and tolerability when given alone or with panitumumab, a treatment for colorectal cancer. Participants include those with solid tumors who have not responded to or are ineligible for standard treatments. The study has two parts Dose Escalation and Dose Expansion. In Dose Escalation, small groups receive increasing doses of ASP5834 alone or with panitumumab only for colorectal cancer patients via intravenous infusion. The medical team reviews side effects to decide dosing for the next group. In Dose Expansion, groups receive the chosen ASP5834 doses alone or with panitumumab. Treatment cycles last 21 or 28 days, repeated until side effects, cancer progression, other treatments, or participant choice ends treatment. Participants will have clinic visits on set days during treatment, with extra visits early on to monitor safety and health. Scans will check cancer changes, and tumor samples may be taken during treatment or if cancer worsens. After treatment ends, participants have health checks every few months to monitor cancer status. The total study participation is expected to last about one year. Researchers measure safety, side effects, tumor response, survival, and drug behavior in the body.
CONDITIONS
Brief Title
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Research Team
A
Astellas Pharma Global Development, Inc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here